Compositions and methods for treating particular chemical addictions and mental illnesses
OwnerJose Pozueloinventor
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions and related methods are disclosed for treating addiction to an array of agents such as heroin, narcotics, cocaine, amphetamines and/or marijuana. Compositions and methods are also disclosed for treating alcoholism and dependence on nicotine intake, such as smoking. Also disclosed are pharmaceutical compositions and related methods for treating various mental illnesses or conditions, such as for example, schizophrenia and manic depressive psychosis.
Claims15
A method for treating at least one of (i) addiction to heroin, narcotics, cocaine, amphetamines, alcohol, nicotine or marijuana;
- and (ii) schizophrenia or manic depressive psychosis, said method comprising:
- providing alpha-methyl-para-tyrosine;
- providing 4-[4-(p-chlorophenyl)-4-hydroxy-piperidino]-4′-fluorobutyrophenone;
- and
- concurrently administering from about 1 mg to about 200 mg of said alpha-methyl-para-tyrosine per kg of patient body weight per day, and from about 0.015 mg to about 1.0 mg of said 4-[4-(p-chlorophenyl)-4-hydroxy-piperidino]-4′-fluorobutyropheneone per kg of patient body weight per day, to a patient in need of such treatment.
A method for treating at least one of (i) addiction to heroin, narcotics, cocaine, amphetamines, alcohol, nicotine or marijuana;
- and (ii) schizophrenia or manic depressive psychosis, said method comprising:
- providing alpha-methyl-para-tyrosine;
- providing 4-[4-(p-chlorophenyl)4-hydroxy-piperidino]-4′-fluorobutyrophenone;
- providing 17-17-(cyclopropylmethyl)-4,5 alpha-epoxy-3, 14 dihydroxymorphinan-6-one;
- providing a urine alkalinizer;
- simultaneously administering from about 15 mg to about 170 mg of said alpha-methyl-para-tyrosine per kg of patient body weight per day, and from about 0.015 mg to about 1.0 mg of said 4-[4-(p-chlorophenyl)-4-hydroxy-piperidino]-4′-fluorobutyrophenone per kg of patient body weight per day, to a patient in need of such treatment;
- administering an effective dosage amount of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-3, 14 dihydroxymorphinan-6-one;
- and
- administering an amount of said urine alkalinizer sufficient to result in a urine pH of greater than 7.8.
Dependencies are inferred from the claim text.